Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: In vitro analyses

Antiviral Research

Volumn 36, Issue 2, 1997, Pages 91-97

  Mulato, A S ^a   Cherrington, J M ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Adefovir dipivoxil; Drug combinations; HIV; PMEA; PMPA

Indexed keywords

ACYCLIC NUCLEOSIDE; ADEFOVIR; ADEFOVIR DIPIVOXIL; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

ADENINE; ANTI-HIV AGENTS; DRUG INTERACTIONS; HIV-1; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; TUMOR CELLS, CULTURED;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0030831418     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(97)00043-0     Document Type: Article

References (43)

1. Balzarini J., Perno C.F., Schols D., De Clercq E. Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes. Biochem. Biophys. Res. Commun. 178:1991;329-335.
2. Balzarini J., Holy A., Jindrich J., Naesens L., Snoeck R., Schols D., De Clercq E. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in vivo antiretrovirus activities of the (R)-9-(2-phosphonomethoxypropyl) derivatives of adenine and 2,6-diaminopurine. Antimicrob. Agents Chemother. 37:1993;332-338.
3. Cavert W., Notermans D.W., Staskus K., Wietgrefe S.W., Zupancic M., Gebhard K., Henry K., Zhang Z.Q., Mills R., McDade H., Goudsmit J., Danner S.A., Haase A.T. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science. 276:1997;960-964.
4. Cherrington J.M., Allen S.J.W., Bischofberger N., Chen M.S. Kinetic interaction of the diphosphates of 9-(2-phophonylmethoxyethyl)adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases α, β and γ Antiviral Chem. Chemother. 6:1995;217-221.
5. Cherrington J.M., Mulato A.S., Fuller M.D., Chen M.S. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro. Antimicrob. Agent Chemother. 40:1996;2212-2216.
6. Cherrington, J.M., Chandok, R., Mulato, A.S., Lamy, P.D., Mitsuya, H., Wainberg, M., 1997. In vitro selection and characterization of HIV-1 variants with reduced susceptibility to PMPA. 6th Int. Workshop on HIV Drug Resistance, Abstract 26. St. Petersburg, FL.
7. De Clercq E., Holy A., Rosenberg I., Sakuma T., Balzarini J., Maudal P.C. A novel selective broad-spectrum anti-DNA virus agent. Nature. 323:1986;464-467.
8. De Clercq E., Sakuma T., Baba M., Pauwels R., Balzarini J., Rosenberg I., Holy A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines. Antiviral Res. 8:1987;261-272.
9. Deeks, S., Collier, A., Lalezari, J., Pavia, A., Rodrigue, D., Jaffe, H.S., Toole, J., Kahn, J., 1996. A randomized, double-blind, placebo-controlled study of bis-POM PMEA in HIV-infected patients. 3rd Conf. on Retroviruses and Opportunistic Infections, Abstract 407. Washington, DC.
10. Deeks, S., Collier, A., Lalezari, J., Pavia, A., Rodrigue, D., Drew, W.L., Toole, J., Jaffe, H.S., Mulato, A.S., Lamy, P.D., Li, W., Cherrington, J.M., Hellmann, N., Kahn, J., 1997. The safety and efficacy of adefovir dipivoxil, a novel anti-HIV therapy, in HIV infected adults. J. Infect. Dis. (in press).
11. Deminie C.A., Bechtold C.M., Stock D., Alam M., Djang F., Balch A.H., Chou T.C., Prichard M.N., Colonno R.J., Lin P.F. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob. Agents Chemother. 40:1996;1346-1351.
12. de Jong M.D., Boucher C.A.B., Galasso G.J., Hirsch M.S., Kern E.R., Lange J.M.A., Richman D.D. Consensus symposium on combined antiviral therapy. Antiviral Res. 29:1995;5-29.
13. Elion G.B., Singer S., Hitchings G.H. Antagonism of nucleic acid derivatives. J. Biol. Chem. 208:1954;477-488.
14. Foli A., Sogocio K.M., Anderson B., Kavlick M., Saville M.W., Wainberg M.A., Gu X., Cherrington J.M., Mitsuya H., Yarchoan R. In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). Antiviral Res. 32:1996;91-98.
15. Foudraine, N., De Wolf, F., Hoetelmans, R., Portegies, P., Maas, J., Lange, J., 1997. CSF and serum HIV-RNA levels during AZT/3TC and d4T/3TC treatment. 4th Conf. on Retroviruses and Opportunistic Infections, Abstract LB5. Washington, DC.
16. Gu Z., Salomon H., Cherrington J.M., Mulato A.S., Chen M.S., Yarchoan R., Foli A., Sogocio K.M., Wainberg M.A. K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob. Agents Chemother. 39:1995;1888-1891.
17. Haase A.T., Henry K., Zupancic M., Sedgewick G., Gaust R.A., Melroe H., Cavert W., Gebhard K., Staskus K., Zhang Z.Q., Dailey P.J., Balfour H.H. Jr., Erice A., Perelson A.S. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science. 274:1996;985-989.
18. 3). 4th Conf. on Retroviruses and Opportunistic Infections, Abstract LB6. Washington, DC.
19. 3. 4th Conference of Retroviruses and Opportunistic Infections, Abstract LB7. Washington, DC.
20. Hirsch M.S., D'Aquila R.T. Therapy for human immunodeficiency virus infection. New Engl. J. Med. 328:1993;1686-1695.
21. Jacobsen H., Hanggi M., Ott M., Duncan I.B., Owen S., Andreoni M., Vella S., Mous J. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J. Infect. Dis. 173:1996;1379-1387.
22. Katlama, C., Valantin, M.A., Calvez, V., S., Coutelier, A., Descamps, D., Longuet, C., De Sa, M., Bonmarchand, M., Lancar, R., Agut, H., Brun-Vezinet, F., Costagliola, D., 1997. Altis: A pilot open study of d4T/3TC in antiretroviral naive and experienced patients. 4th Conf. on Retroviruses and Opportunistic Infections, Abstract LB4. Washington, DC.
23. Kitchen V.S., Skinner C., Ariyoshi K., Lane E.A., Duncan I.B., Burckhardt J., Burger H.U., Bragman K., Pinching A.J., Weber J.N. Safety and activity of saquinavir in HIV infection. Lancet. 345:1995;952-955.
24. Kuritzkes, D., Shugarts, D., Griffen, A., Bakhtiari, M., Eron, J., Quinn, J., Fallon, M.A., Rubin, M., Benoit, S., 1995. Resistance to lamivudine (3TC) and zidovudine (ZDV) in a phase II comparative trial of 3TC vs ZDV vs 3TC plus ZDV. 4th Int. Workshop on HIV Drug Resistance, Abstract 53. Sardinia.
25. Larder B.A. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J. Gen. Virol. 75:1994;951-957.
26. Larder B.A., Kemp S.D., Harrigan P.R. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 269:1995;696-699.
27. Markowitz, M., Cao, Y., Vesanen, M., Talal, A., Nixon, D., Hurley, A., O'Donovan, R., Pracz, P., Tennerracz, K., Ho, D.D., 1997. Recent HIV infection treated with AZT, 3TC and a potent protease inhibitor. 4th Conf. on Retroviruses and Opportunistic Infections, Abstract LB8. Washington, DC.
28. Markowitz M., Saag M., Powderly W.G., Hurley A.M., Hsu A., Valdes J.M., Henry D., Sattler F., La Marca A., Leanard J.M., Ho D.D. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. New Engl. J. Med. 333:1995;1534-1539.
29. Mellors, J.W., Bazmi, H., Chu, C.K., Schinazi, R.F., 1996. K65R mutation in HIV-1 reverse transcriptase causes resistance to (-)-β-D-dioxolane-guanosine and reverses AZT resistance. 5th Workshop on HIV Drug Resistance, Abstract 7. Whistler, Canada.
30. Mulato A.S., Cherrington J.M., Chen M.S. Anti-HCMV activity of cidofovir in combination with antiviral compounds and immunosuppressive agents: in-vitro analyses. Antiviral Chem. Chemother. 7:1996;203-208.
31. Mulato, A.S., Lamy, P.L., Li, W., Miller, M.D., Cherrington, J.M., 1997. Genotypic Characterization of HIV-1 variants isolated from AIDS patients treated with adefovir dipivoxil (Bis-POM PMEA). 6th Int. Workshop on HIV Drug Resistance, Abstract 24. St. Petersburg.
32. Pauwels R., Balzarini J., Schols D., Baba M., Desmyter J., Holy A., De Clercq E. Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob. Agents Chemother. 32:1988;1025-1030.
33. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 271:1996;1582-1586.
34. Perno C.F., Balestra E., Aquaro S., Panti S., Cenci A., Lazzarino G., Tavazzi B., Di Pierro D., Balzarini J., Calio R. Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phophonylmethoxyethyl) adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines. Mol. Pharmacol. 50:1996;359-366.
35. Prichard M.N., Shipman C. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14:1990;181-206.
36. Prichard, M.N., Aseltine, K.R., Shipman, C., 1993. MacSynergy II. Version 1.
37. Richman D.D., Havlir D., Corbeil J., Looney D., Ignacio C., Spector S.A., Sullivan J., Cheeseman S., Barringer K., Pauletti D., Shih C.-K., Myers M., Griffin J. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1994;1660-1666.
38. St. Clair M.H., Martin J.L., Tudor-Williams G., Bach M.M., Vavro C.L., King D.M., Kellam P., Kemp S.D., Larder B.A. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 253:1991;1557-1559.
39. + T-cell counts in HIV-infected patients. Ann. Intern. Med. 124:1996;1039-1050.
40. Tachedjian, G., Mellors, J., Bazmi, H., Birch, C., Mills, J., 1996. Zidovudine resistance is suppressed by mutations conferring resistance of HIV-1 to foscarnet. 5th Workshop on HIV Drug Resistance, Abstract 2. Whistler, Canada.
41. Tsai C.C., Follis K.E., Sabo A., Beck T., Grant R.F., Bischofberger N., Benveniste R.E., Black R. Prevention of simian immunodeficiency virus infection in macaques by 9-(2-phosphonylmethoxyethyl)adenine (PMPA). Science. 270:1995;1197-1199.
42. Van Rompay K.K.A., Cherrington J.M., Marthas M.L., Berardi C.J., Mulato A.S., Spinner A., Tarara R.P., Canfield D.R., Telm S., Bischofberger N., Pedersen N.C. 9-[2-(phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob. Agents Chemother. 40:1996;2586-2591.
43. Wong, J.K., Gunthard, H.F., Havlir, D.V., Haase, A.T., Zhang, Z.Q., Kwok, S., Ignacio, C.C., Keating, N.A., Chodakewitz, J., Emini, E., Meibohm, A., Jonas, L., Richman, D.D., 1997. Reduction of HIV in blood and lymph nodes after potent antiretroviral therapy. 4th Conf. on Retroviruses and Opportunistic Infections, Abstract LB10. Washington, DC.